FY2025 Earnings Forecast for ELAN Issued By Leerink Partnrs

Elanco Animal Health Incorporated (NYSE:ELAN) – Analysts at Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for Elanco Animal Health in a report issued on Wednesday, November 5th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings of $0.93 per share for the year, up from their previous estimate of $0.90. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The business’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS.

ELAN has been the subject of a number of other research reports. Stifel Nicolaus increased their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Weiss Ratings cut Elanco Animal Health from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. UBS Group boosted their target price on Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Leerink Partners raised Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target for the company in a research note on Thursday, July 17th. Finally, Zacks Research lowered Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $20.29.

Elanco Animal Health Stock Performance

ELAN stock opened at $22.90 on Monday. The firm has a 50 day simple moving average of $20.35 and a 200 day simple moving average of $16.45. Elanco Animal Health has a 52 week low of $8.02 and a 52 week high of $23.00. The stock has a market cap of $11.38 billion, a P/E ratio of 381.73, a P/E/G ratio of 3.03 and a beta of 1.71. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40.

Institutional Trading of Elanco Animal Health

Large investors have recently made changes to their positions in the stock. SJS Investment Consulting Inc. raised its stake in shares of Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after acquiring an additional 1,333 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its holdings in Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after purchasing an additional 900 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of Elanco Animal Health by 79.3% in the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after purchasing an additional 951 shares during the period. Allworth Financial LP lifted its stake in shares of Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after buying an additional 2,090 shares during the last quarter. Finally, Fifth Third Bancorp boosted its holdings in shares of Elanco Animal Health by 3,018.3% during the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after buying an additional 2,807 shares during the period. Institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.